Phase
Startup
Sinntaxis
Sinntaxis AB is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke. Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.
Tomas Eriksson has more than 10 years’ experience as CEO and co-founder of A1M Pharma, and 20+ years of experience in international marketing and sales, primarily within medical technology and diagnostics. He has also been involved in a number of early stage projects in life science, with a focus on business development and financing.
Did you know?
The Sinntaxis approach has shown improved restoration of brain function, enhancing the speed and extent of recovery after stroke.
Accelerated drug development in oncology
Simplify medicine information through digital services
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Continuous monitoring of lung function
Individualised information of the intestinal flora
Digital service for patients
Digital tool for meeting an allergy doctor
Mobile systems for movement analysis
Innovative solutions for better health care
Medical device that reduces pain during vein operation
Prebiotics for irritable bowel syndrome
Healthtech for children with eating challenges
Digital health management tool
Nanotechnology based infection control
Therapeutics after stroke
Measuring thyroid hormone levels
Gene editing analysis solution
Stroke detection device
Cost-effective & rapid COVID-19 diagnostic test
Wound treatment gel
